An breakthrough leads to a potential drug for a rare disease for a treatment for myopathie

In 5 seconds

The FDA grants a Fast Track designation for a treatment for primary mitochondrial myopathy.

A drug candidate discovered by Peter W. Schiller, Director of the Chemical Biology and Peptide Research unit at the Institut de recherches cliniques de Montréal (IRCM) and Research Professor in the Department of Pharmacology of the Université de Montréal, has been granted Fast Track designation by the Food and Drug Administration (FDA) for the treatment of primary mitochondrial myopathy. The candidate, elamipretide (formerly known as Bendavia), is being developed by Stealth BioTherapeutics Inc.

Read on the IRCM website.

About the IRCM

The IRCM (Institut de recherches cliniques de Montréal) is a renowned biomedical research institute located in the heart of Montréal's university district. Founded in 1967, it is currently comprised of 35 research units and four specialized research clinics (cholesterol, cystic fibrosis, diabetes and obesity, hypertension). The IRCM employs nearly 425 people. It is affiliated with the Université de Montréal, and the IRCM Clinic is associated to the Centre hospitalier de l'Université de Montréal (CHUM). It also maintains a long-standing association with McGill University. The IRCM is funded by the Quebec ministry of Economy, Innovation and Exports (Ministère de l'Économie, de l'Innovation et des Exportations). For more information,

Media resources